Fig. 7
From: Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain
In vivo anti-tumor efficacy of Jchain HLA-A1, A24, A3 and A11 restricted TCR-transduced CD8 T cells. NSG mice engrafted with 2 × 106 U266 multiple myeloma cells transduced with Luc2 luciferase and HLA-A1, -A11, -A24 or wildtype (WT) were i.v. injected with 3–6 × 106 TCR-transduced CD8 T cells after 21 days. CD8 T cells were separately transduced with Jchain HLA-A1 (5D12), -A3 (5C8), -A11 (16C7), -A24 (A24) or control CMV (pp65-NLV-HLA-A2) TCR and enriched for mTCR expression by MACS. T cells were infused 10 days after re-stimulation. Tumor outgrowth was frequently tracked by bioluminescence imaging. Data representative of two independent experiments. A Raw bioluminescent images of Jchain HLA-A1 TCR-treated mice and control CMV TCR-treated mice. B Mean and standard deviations of tumor signal (average radiance) over time on the ventral side in Jchain HLA-A1 TCR-treated (upper left), Jchain HLA-A3 TCR-treated (lower left), Jchain HLA-A24 TCR-treated (upper right) and Jchain HLA-A11 TCR-treated (lower right) mice compared to CMV TCR control mice. Statistics depict two-way ANOVA comparing groups per timepoint with Sidak’s multiple comparisons post hoc test